Trial Profile

First in human trial of ROR1 CAR-T in china

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 12 May 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ONCT-808 (Primary)
Indications Haematological malignancies
Focus Adverse reactions; First in man
Sponsors Oncternal Therapeutics, Inc.

Most Recent Events

06 May 2021 According to an Oncternal Therapeutics, Inc. media release, dosing is expected in the first half of 2022.
14 Jan 2021 According to an Oncternal Therapeutics, Inc. media release, the company expects to initiate this trial in the second half of 2021.
06 Aug 2020 According to an Oncternal Therapeutics media release, first-in-human dosing in China is anticipated in 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com